Trial reportSexually transmitted infections2013
High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects.
Trial report in Sexually transmitted infections, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years.
HPV Vaccination and Infectivity Reduction in HPV-positive Women
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Uptake of human papilloma virus vaccine and its determinants among females in East Africa: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Estimating incidence rates of grouped HPV types: A systematic review and comparison of the impact of different epidemiological assumptions.Papillomavirus research (Amsterdam, Netherlands) · 2019Pooled it
- Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.The Lancet. Global health · 2025Trial
- Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.Nature medicine · 2023Trial
- Efficacy of single-dose HPV vaccination among young African women.NEJM evidence · 2022Trial
- Trial
- Association Between Female Genital Schistosomiasis and High-Risk Human Papillomavirus Among Women of Reproductive Age in Zambia: The Schista Study.The Journal of infectious diseases · 2026Article
- Understanding the Dynamics of Human Papillomavirus and Diagnostic Discrepancies in Cervical Pathology: A Single Center Experience.Diagnostics (Basel, Switzerland) · 2023Article
- Genital Microbiota of Women From Six Ethnic Groups With and Without Human Papillomavirus Infection in Shangri-La, China.Frontiers in cellular and infection microbiology · 2022Article
- Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco.Frontiers in public health · 2022Review
- Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women.Infectious agents and cancer · 2021Article
- A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial.Contemporary clinical trials · 2021Article
- Comprehensive Cervical Cancer Prevention in Tanzania (CONCEPT) study: Cohort profile.BMJ open · 2020Article
- HPV prevalence around the time of sexual debut in adolescent girls in Tanzania.Sexually transmitted infections · 2020Article
- Cervical cancer in Tanzania: A systematic review of current challenges in six domains.Gynecologic oncology reports · 2019Review
- Oncogenic human papillomavirus infection and genotypes characterization among sexually active women in Tenkodogo at Burkina Faso, West Africa.Papillomavirus research (Amsterdam, Netherlands) · 2018Article
- Association between Hormonal Contraception and Injuries Induced by Human Papillomavirus in the Uterine Cervix.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018Article
- Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil.BMC women's health · 2018Article
- Article
- Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique.BMJ open · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
objectivesWe measured the prevalence and incidence of human papillomavirus (HPV) infection in young female subjects recruited for a safety and immunogenicity trial of the bivalent HPV-16/18 vaccine in Tanzania.
methodsHealthy HIV negative female subjects aged 10-25 years were enrolled and randomised (2:1) to receive HPV-16/18 vaccine or placebo (Al(OH)3 control). At enrolment, if sexually active, genital specimens were collected for HPV DNA, other reproductive tract infections and cervical cytology. Subjects were followed to 12 months when HPV testing was repeated.
resultsIn total 334 participants were enrolled; 221 and 113 in vaccine and control arms, respectively. At enrolment, 74% of 142 sexually active subjects had HPV infection of whom 69% had >1 genotype. Prevalent infections were HPV-45 (16%), HPV-53 (14%), HPV-16 (13%) and HPV-58 (13%). Only age was associated with prevalent HPV infection at enrolment. Among 23 girls who reported age at first sex as 1 year younger than their current age, 15 (65.2%) had HPV infection. Of 187 genotype-specific infections at enrolment, 51 (27%) were present at 12 months. Overall, 67% of 97 sexually active participants with results at enrolment and 12 months had a new HPV genotype at follow-up. Among HPV uninfected female subjects at enrolment, the incidence of any HPV infection was 76 per 100 person-years.
conclusionsAmong young women in Tanzania, HPV is highly prevalent and acquired soon after sexual debut. Early HPV vaccination is highly recommended in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.